Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia. research hub

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study).

This study is testing a new medicine called Panzyga to see if it can help prevent serious infections in people with a type of blood cancer called chronic lymphocytic leukaemia (CLL). It wants to find out if taking Panzyga reduces how often these infections happen.